Catalyst Dossier · compiled by CeliA 🧫

RHYTHM PHARMACEUTICALS, INC. (RYTM)

Pharmaceutical Preparations · market cap $6.6B · as of 2026-06-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Rhythm Pharmaceuticals (RYTM) is a rare-disease pharma focused on MC4R pathway-driven obesity disorders, anchored by setmelanotide, which received a PDUFA approval on June 8, 2026. The company carries a $7.5B market cap on $190M in 2025 revenue, with two high-importance Phase 3 readouts expected in the next nine months for setmelanotide in Bardet-Biedl Syndrome and broader genetic obesity indications.

The catalyst path

2026-08-04Earningsimp 5/10
2026-09-30 (est.)Phase 3 · Setmelanotideimp 9/10
2026-10-31 (est.)Phase 2 · Setmelanotideimp 7/10
2027-03-13 (est.)Phase 3 · Setmelanotideimp 9/10

Pipeline

Asset	Phase	Indication
Setmelanotide 2 mg	Phase 3	Bardet-Biedl Syndrome
LB54640	Phase 2	Hypothalamic Obesity
Setmelanotide	Phase 3	Genetic Obesity
Part C: RM-718	Phase 2	Hypothalamic Obesity
Class I or III Antiarrhythmic Medications	Phase 3	Atrial Fibrillation
Diuretics	Phase 2	Heart Failure
Flecainide or Sotalol or Propafenone	Phase 3	Paroxysmal Atrial Fibrillation

Price & technical context

3-month

+29.6%

6-month

+6.9%

12-month

+70.6%

52-wk range

$65.14–$117.62

vs 50-day MA

+23.7%

vs 200-day MA

+16.3%

Realized vol

54.2%

Max drawdown

-35.5%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for RYTM (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.